Quick Answer
NERVGEN PHARMA CORP. reported net income of -C$44.12 million for fiscal year 2025, reported under IFRS on Form 20-F.
Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted.
NERVGEN PHARMA CORP. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -C$44.12M -81.9% |
-C$24.25M | — |
| Basic EPS | -C$0.61 -69.4% |
-C$0.36 | — |
| Diluted EPS | -C$0.61 -69.4% |
-C$0.36 | — |
| Total Assets | C$23.21M +19.1% |
C$19.49M | — |
| Total Liabilities | C$19.73M +16.7% |
C$16.91M | — |
| Total Equity | C$3.48M +34.9% |
C$2.58M +228.2% |
-C$2.01M |
| Operating Cash Flow | -C$19.50M -15.8% |
-C$16.84M | — |
| R&D Expense | C$13.91M -12.0% |
C$15.81M | — |
- NERVGEN PHARMA CORP. reported net income of -C$44.12 million for fiscal year 2025.
- That is a decrease of -81.9% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported basic eps of C$-0.61 per share for fiscal year 2025.
- That is a decrease of -69.4% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported diluted eps of C$-0.61 per share for fiscal year 2025.
- That is a decrease of -69.4% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported total assets of C$23.21 million for fiscal year 2025.
- That is an increase of +19.1% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported total liabilities of C$19.73 million for fiscal year 2025.
- That is an increase of +16.7% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported total equity of C$3.48 million for fiscal year 2025.
- That is an increase of +34.9% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported operating cash flow of -C$19.50 million for fiscal year 2025.
- That is a decrease of -15.8% versus the prior fiscal year.
- NERVGEN PHARMA CORP. reported r&d expense of C$13.91 million for fiscal year 2025.
- That is a decrease of -12.0% versus the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 19, 2026.
Last verified: